Complete financial analysis of Blueprint Medicines Corporation (0HOJ.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Blueprint Medicines Corporation, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Studio Retail Group plc (STU.L) Income Statement Analysis – Financial Results
- DigiAsia Corp. (FAASW) Income Statement Analysis – Financial Results
- RCM Beteiligungs AG (RCMN.DE) Income Statement Analysis – Financial Results
- Global Clean Energy, Inc. (GCEI) Income Statement Analysis – Financial Results
- Mojave Brands Inc. (MOJO.CN) Income Statement Analysis – Financial Results
Blueprint Medicines Corporation (0HOJ.L)
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 249.38M | 204.04M | 180.08M | 793.74M | 66.51M | 44.52M | 21.43M | 27.77M | 11.40M | 0.00 | 0.00 |
| Cost of Revenue | 12.80M | 17.81M | 17.93M | 425.00K | 0.00 | 243.62M | 144.69M | 81.13M | 48.59M | 31.84M | 15.93M |
| Gross Profit | 236.58M | 186.22M | 162.15M | 793.31M | 66.51M | -199.10M | -123.26M | -53.36M | -37.19M | -31.84M | -15.93M |
| Gross Profit Ratio | 94.87% | 91.27% | 90.04% | 99.95% | 100.00% | -447.20% | -575.29% | -192.13% | -326.21% | 0.00% | 0.00% |
| Research & Development | 427.72M | 477.42M | 601.03M | 326.86M | 331.45M | 243.62M | 144.69M | 81.13M | 48.59M | 31.84M | 15.93M |
| General & Administrative | 278.24M | 219.27M | 181.79M | 148.34M | 96.39M | 47.93M | 27.99M | 19.22M | 14.46M | 7.89M | 5.07M |
| Selling & Marketing | 16.90M | 18.10M | 13.50M | 9.40M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 295.14M | 237.37M | 195.29M | 157.74M | 96.39M | 47.93M | 27.99M | 19.22M | 14.46M | 7.89M | 5.07M |
| Other Expenses | 0.00 | 8.95M | 7.80M | -366.00K | -100.00K | 10.46M | 3.35M | 551.00K | -429.00K | -98.00K | 226.00K |
| Operating Expenses | 722.86M | 723.74M | 804.13M | 484.60M | 427.84M | 291.55M | 172.67M | 100.35M | 63.04M | 39.73M | 21.00M |
| Cost & Expenses | 735.66M | 741.55M | 822.06M | 485.03M | 427.84M | 291.55M | 172.67M | 100.35M | 63.04M | 39.73M | 21.00M |
| Interest Income | 0.00 | 17.75M | 2.39M | 6.60M | 13.73M | 10.64M | 3.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 16.77M | 0.00 | 0.00 | 13.73M | 73.00K | 221.00K | 469.00K | 696.00K | 453.00K | 138.00K |
| Depreciation & Amortization | 11.67M | 20.10M | 12.79M | 12.35M | 10.25M | 4.25M | 1.58M | 1.58M | 948.00K | 622.00K | 501.00K |
| EBITDA | -470.36M | -515.42M | -628.30M | 308.71M | -356.07M | -242.78M | -149.67M | -70.44M | -51.13M | -39.11M | -20.50M |
| EBITDA Ratio | -188.61% | -263.44% | -356.50% | 38.89% | -543.25% | -531.36% | -690.27% | -259.35% | -456.78% | 0.00% | 0.00% |
| Operating Income | -486.28M | -549.25M | -648.46M | 302.15M | -366.59M | -247.03M | -149.48M | -73.61M | -53.02M | -39.83M | -20.77M |
| Operating Income Ratio | -194.99% | -269.19% | -360.10% | 38.07% | -551.16% | -554.86% | -697.64% | -265.04% | -465.10% | 0.00% | 0.00% |
| Total Other Income/Expenses | -19.74M | -14.76M | 897.00K | 6.23M | 13.63M | 10.39M | 3.13M | 82.00K | -1.13M | -551.00K | 88.00K |
| Income Before Tax | -506.02M | -552.28M | -641.08M | 314.94M | -347.69M | -236.64M | -148.12M | -72.50M | -52.77M | -40.29M | -20.91M |
| Income Before Tax Ratio | -202.91% | -270.68% | -356.00% | 39.68% | -522.75% | -531.53% | -691.30% | -261.04% | -462.89% | 0.00% | 0.00% |
| Income Tax Expense | 968.00K | 5.24M | 3.00M | 1.06M | -18.99M | 10.46M | 1.99M | -562.00K | -681.00K | 355.00K | 364.00K |
| Net Income | -506.98M | -557.52M | -644.09M | 313.88M | -328.70M | -236.64M | -148.12M | -72.50M | -52.77M | -40.29M | -20.91M |
| Net Income Ratio | -203.30% | -273.24% | -357.67% | 39.54% | -494.20% | -531.53% | -691.30% | -261.04% | -462.89% | 0.00% | 0.00% |
| EPS | -8.37 | -9.35 | -11.01 | 5.76 | -6.87 | -5.39 | -3.92 | -2.64 | -2.89 | -3.08 | -1.60 |
| EPS Diluted | -8.37 | -9.35 | -11.01 | 5.59 | -6.87 | -5.39 | -3.92 | -2.64 | -2.89 | -3.08 | -1.60 |
| Weighted Avg Shares Out | 60.56M | 59.64M | 58.52M | 54.53M | 47.83M | 43.87M | 37.79M | 27.49M | 18.24M | 13.08M | 13.08M |
| Weighted Avg Shares Out (Dil) | 60.56M | 59.64M | 58.52M | 56.17M | 47.83M | 43.87M | 37.79M | 27.49M | 18.24M | 13.08M | 13.08M |
Source: https://incomestatements.info
Category: Stock Reports